The global erectile dysfunction drugs market will decelerate at a CAGR of 4.5% during the forecast period of 2013 to 2019. In 2012, the global erectile dysfunction drugs market stood at US$4.3 billion and is expected to reach a market value of US$3.4 billion by end of 2019.
Albany, NY -- (SBWIRE) -- 11/19/2015 -- Erectile dysfunction (ED) is the inability to achieve or maintain satisfactory erection of penis during sexual intercourse. It is usually an age related condition but can also be triggered by psychological factors. It may occur due to various reasons such as smoking, sedentary lifestyle and administration of certain drugs such as antidepressants, psychotropic drugs, antihypertensive and recreational drugs. Presently, oral phosphodiesterase type 5 inhibitors (PDE 5) commonly form the first line of treatment prescribed by doctors for ED. These include drugs namely, Viagra (sildenafil citrate), Cialis (tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil) and Zydena (udenafil). The demand for erectile dysfunction drugs is high and is continuously rising as it caters to the needs of the growing elderly population and the high incidence rates of chronic disorders comprising hypertension, renal diseases and diabetes, neurological disorders and hormonal insufficiencies.
Complete Report with TOC @ http://www.mrrse.com/erectile-dysfunction-drugs
Erectile dysfunction drugs market is expected to witness a decline across the globe, by the end of the forecast period, i.e. by 2019, due to patent expiration of the key revenue generating drug Viagra outside the U.S. in 2013. In addition, Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG are also scheduled to lose their patent exclusivities during the forecast period. The loss of patent and marketing exclusivity will lead to a drastic reduction in revenues and in turn provide an opportunity to generic manufacturers to launch their own versions of these brands. Moreover, low success rate of novel drug formulations owing to weak pipeline development will also account for the downturn of the overall erectile dysfunction drugs market.
Pfizer's Viagra was the largest revenue generator in 2012, in the total market, owing to its foremost presence in the pharmaceutical market for erectile dysfunction treatment. Viagra has maintained its blockbuster status till date, recording billion dollar sales every year for Pfizer, Inc. The primary competitors on the market for Viagra are Cialis (tadalafil) by Eli Lilly & Co. and Levitra (vardenafil) by Bayer AG.
Geographically, North America dominated the global erectile dysfunction drugs market and is expected to continue to lead in terms of revenue generation throughout the forecast period. North America is considered as the most lucrative market for erectile dysfunction drugs owing to the presence of blockbuster drugs Viagra and Cialis in the U.S. market through 2019. The North American market for erectile dysfunction drugs was valued at USD 2,098.4 million in the year 2012. However, loss of patent exclusivities for Cialis (tadalafil) and Levitra/Staxyn (vardenafil) within the forecast period are expected to hamper market growth, though to a lesser extent. Factors such as increased market consolidation (due to influx of generics and weak pipeline development), cost containment measures coupled with introduction of cheaper products will result in rapid adoption of these drugs in the emerging markets. The leading players in the market for branded erectile dysfunction drugs are Pfizer, Inc., Eli Lilly & Co., Bayer AG, Dong-A Pharmaceutical Co. Ltd and Vivus, Inc.
Request a Sample Copy of the Report @ http://www.mrrse.com/sample/873
MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.